HomeMarket NewsMicro Cap StocksWhy MariMed Inc.'s Q3 Results Point to Sustained Success Beyond Federal Weed...

Why MariMed Inc.’s Q3 Results Point to Sustained Success Beyond Federal Weed Reform

Actionable Trade Ideas

always free

untitled 2

MariMed Inc. (MRMD) recently unveiled its third-quarter earnings report for the three months ending Sept. 30, 2023, showcasing impressive results and projections that reinforce its position as a pioneering multi-state operator (MSO) in the cannabis industry.

Renowned cannabis expert Pablo Zuanic, senior analyst at Zuanic & Associates, highlights MariMed’s undervalued status compared to its MSO peers and projects its ascent to a top 10 MSO by 2025.

Amidst this optimistic outlook, MariMed’s Q3 performance is a testament to its robust operational capabilities in key states such as Illinois, Massachusetts, Maryland, Ohio, with upcoming expansions in Missouri and Delaware. The company reported a revenue surge to $38.8 million, marking a noteworthy year-over-year growth of over 14%.

Zuanic underscores MariMed’s commendable gross margins, high SGA efficiency, competitive EBITDA margins, and positive operating cash flow, setting it apart from many industry counterparts.

The Financial Landscape – Q3 Insights

  • The gross profit escalated to $16.8 million from $16.1 million in the previous year’s corresponding period.
  • Gross margin experienced a slight dip to 43.4%, down from 47.7% in the prior year’s Q3.
  • Total operating expenses rose to $13.5 million from $10.4 million in the same quarter of the previous year.
  • Income from operations totaled $3.3 million, a decrease from $5.7 million in the Q3 of 2023.
  • The company reported a net loss of $4.2 million, in contrast to a net income of $2.7 million in the prior year’s period.
  • Adjusted EBITDA stood positive at $6 million, in comparison to $8.6 million in the previous year’s Q3.

2023 Outlook and Beyond

MariMed’s outlook for the full-year 2023 encompasses:

  • Anticipated revenue within the range of $148 million to $150 million
  • Approximately 45% gross margin
  • Non-GAAP Adjusted EBITDA spanning $27 million to $32 million
  • Projected capital expenditures between $22 million to $25 million

MRMD Price Action

MariMed’s shares observed a 1.5625% decline, trading at $0.315 per share at the time of reporting on Thursday morning.

Insights and Opportunities

Experts believe that the cannabis industry is poised for unprecedented growth, with significant opportunities for potential double-digit gains. Join Benzinga PotProfits to explore promising cannabis stocks, curated by industry expert Michael Berger, ensuring you don’t miss out on the green rush.

Stay tuned for the release of the next potential winners by Michael Berger, offering valuable insights and ticker symbols for prospective gains.


Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.